Levetiracetam Tillomed

Levetiracetam, the active ingredient in Levetiracetam Tillomed, is an anticonvulsant presented as an intravenous solution for intravenous use. It is employed to treat partial, generalized tonic‑clonic and myoclonic seizures in patients with epilepsy, and is indicated for adult and pediatric patients when oral therapy is not feasible.

GNH USA supplies Levetiracetam Tillomed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, ensuring consistent quality and regulatory conformity across markets and reliable delivery timelines.

Levetiracetam is an anticonvulsant that acts on neuronal excitability to control various seizure types.

Partial seizures: reduces frequency of focal seizures in epilepsy patients. Generalized tonic‑clonic seizures: helps prevent convulsive episodes in generalized epilepsy. Myoclonic seizures: decreases occurrence of rapid muscle jerks in appropriate patients.

Levetiracetam may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Fatigue: feeling unusually tired or weak. - Somnolence: increased sleepiness or drowsiness. - Irritability: mood changes including agitation or hostility.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, difficulty breathing. - Suicidal ideation: new or worsening thoughts of self‑harm. - Stevens‑Johnson syndrome: rare skin blistering condition. - Rhabdomyolysis: muscle breakdown with dark urine.

Levetiracetam requires careful consideration of patient‑specific factors and monitoring. - Renal impairment: adjust dose in patients with reduced kidney function. - Hepatic impairment: monitor liver function in patients with liver disease. - Psychiatric symptoms: observe for mood changes or depression. - Pregnancy: safety unknown; weigh benefits versus risks. - Concomitant CNS depressants: use caution as combined sedation may increase. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Levetiracetam has a relatively low interaction profile, but certain combinations warrant attention.

Major Interactions (Avoid): - Probenecid: may increase levetiracetam plasma levels. - Antiepileptic drugs that markedly lower seizure threshold: may reduce levetiracetam efficacy.

Moderate Interactions (Monitor Closely): - Carbamazepine: may modestly reduce levetiracetam concentration. - Benzodiazepines: may enhance sedative effects. - Co‑administration with other renally cleared drugs: monitor renal function.